BICARA THERAPEUTICS
Bicara Therapeutics is a clinical-stage biotechnology startup focused on developing dual-action biologics. The business is developing bifunctional antibodies that are designed to deliver an immunomodulatory payload directly to the tumor microenvironment, assisting cancer patients in increasing immune cell activity and potentially providing long-term efficacy.
BICARA THERAPEUTICS
Industry:
Biopharma Biotechnology Life Science Oncology Therapeutics
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.bicara.com
Total Employee:
11+
Status:
Active
Total Funding:
313 M USD
Technology used in webpage:
Euro CrUX Dataset CrUX Top 10m
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Surface Oncology
Surface Oncology develops next-generation cancer immunotherapy treatments based on proprietary discoveries.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
2023-10-01
Advisor
2021-08-01
Current Employees Featured
Ryan Cohlhepp President & Chief Operating Officer @ Bicara Therapeutics
President & Chief Operating Officer
Lara S. Meisner Chief Legal Officer @ Bicara Therapeutics
Chief Legal Officer
2023-11-01
David Raben Chief Medical Officer @ Bicara Therapeutics
Chief Medical Officer
2023-07-01
Claire Mazumdar Founding CEO @ Bicara Therapeutics
Founding CEO
2020-01-01
Investors List
F-Prime Capital
F-Prime Capital investment in Series C - Bicara Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Bicara Therapeutics
PremjiInvest
PremjiInvest investment in Series C - Bicara Therapeutics
Piper Heartland Healthcare Capital
Piper Heartland Healthcare Capital investment in Series C - Bicara Therapeutics
Bioqube Ventures
Bioqube Ventures investment in Series C - Bicara Therapeutics
Omega Funds
Omega Funds investment in Series C - Bicara Therapeutics
The Rise Fund
The Rise Fund investment in Series C - Bicara Therapeutics
Braidwell
Braidwell investment in Series C - Bicara Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Bicara Therapeutics
Eight Roads Ventures
Eight Roads Ventures investment in Series C - Bicara Therapeutics
Key Employee Changes
Official Site Inspections
http://www.bicara.com Semrush global rank: 4.75 M Semrush visits lastest month: 1.92 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Bicara Therapeutics"
About - Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators.See details»
Bicara Therapeutics - Crunchbase Company Profile & Funding
Bicara Therapeutics may be growing as it has successfully raised a significant amount of capital in a recent funding round. The company closed a new series C funding round, raising over one …See details»
Investor FAQs • Bicara Therapeutics Inc.
Bicara Therapeutics is headquartered at 116 Huntington Avenue, Suite 703, Boston, MA 02116. When was Bicara Therapeutics founded? Bicara Therapeutics was incorporated in December …See details»
News - Bicara Therapeutics
Bicara In The NewsSee details»
SEC Filing • Bicara Therapeutics Inc.
Mar 27, 2025 Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors.See details»
Bicara Therapeutics - Funding, Financials, Valuation
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.See details»
Bicara Therapeutics - VentureRadar
"Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the targeted therapy and tumor modulators.See details»
Press Releases • Bicara Therapeutics Inc.
Mar 27, 2025 View Bicara Therapeutics Inc. releases, including company news, investor relations information and more.See details»
Bicara Therapeutics Company Profile | Management and
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of …See details»
Bicara Therapeutics - Advisory and Governance | The Org
About The Advisory and Governance team at Bicara Therapeutics provides strategic guidance and oversight to ensure that the company’s initiatives align with its mission of developing …See details»
Bicara Therapeutics Company Profile - Office Locations ... - Craft
Oct 29, 2024 Bicara Therapeutics has 1 employees at their 1 location. See insights on Bicara Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
SEC Filings • Bicara Therapeutics Inc.
View financial statements and other formal documents submitted to the U.S. Securities and Exchange Commission (SEC) for Bicara Therapeutics Inc..See details»
Bicara debuts with $40M from Biocon to bankroll bifunctional …
Mar 15, 2021 Bicara launches with $40 million in seed money from Biocon, one of the top biopharma companies in India, to develop a pipeline of bifunctional antibodies.See details»
Biocon accused of committing IP theft to create cancer biotech …
Oct 24, 2024 Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company have been hit with accusations of intellectual …See details»
Bicara Therapeutics - Contacts, Employees, Board Members
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.See details»
Bicara Therapeutics Expands Board of Directors with …
BOSTON, Mass., August 15, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today …See details»
Bicara Therapeutics Announces Upcoming Presentations at AACR …
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional …See details»
Bicara Therapeutics Reports Fourth Quarter and Full Year
Mar 27, 2025 About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to …See details»
Tunisia Tutup Kamp Penampung 20.000 Migran Tak Berdokumen
17 hours ago Hidayatullah.com– Tunisia menutup kamp-kamp tempat penampungan puluhan ribu migran tak berdokumen dari kawasan sub-Sahara Afrika, menyusul maraknya kampanye …See details»
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 …
Mar 27, 2025 Bicara’s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal …See details»